Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HORIZON
2020-002431-30Phase 2Unknown
- Sponsor
- Gyroscope Therapeutics
- Start
- Jul 2020
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GT005 in dry age-related macular degeneration and age-related macular degeneration (AMD) (3 arms), sponsored by Gyroscope Therapeutics. Status: unknown.
02
Drugs
GT005
03
Conditions
dry age-related macular degenerationage-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2020-002431-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002431-30.